Clinical Trial

A US-Uruguay collaboration is using novel REJOIN-seq tech to find hidden RNA triggers of lupus, paving the way for safer, non-immunosuppressive drugs.

AIRNA has dosed the first patient with AIR-001, an RNA-editing drug that could treat both the lung and liver damage of a devastating genetic disease.

A new trial for advanced liver cancer tests visugromab, a drug aiming to overcome immunotherapy resistance and reverse debilitating cancer-related wasting.

A new botanical drug candidate, NFL-102, targets the deep neural roots of addiction, moving beyond symptom management to offer a lasting cure for smokers.

A groundbreaking trial testing if a coffee infused with an ancient herb can slow prostate cancer recurrence is nearing completion, offering hope for a new era.

A long-acting ketamine injection shows promise in treating severe depression without the harsh side effects and monitoring, potentially expanding access for millions.

With record revenue and A-list fans, British MedTech firm LYMA is doubling down on the US market, blending clinical data with celebrity appeal.

A $10M investment from BVF Partners propels Entera Bio’s revolutionary oral osteoporosis drug into a pivotal Phase 3 trial, a major step for patients.

With promising clinical data, Clarametyx promotes key executives to accelerate its novel attack on chronic respiratory disease biofilms. Jennifer Anderson reports.

A novel triple-action topical spray for male pattern baldness enters a pivotal clinical trial, potentially disrupting a multi-billion dollar market.

AvenCell has dosed the first patient with AVC-203, a novel allogeneic CAR-T therapy, aiming to make advanced cancer treatment more accessible and effective.

A breakthrough test for Parkinson's is expanding worldwide, promising earlier, more accurate diagnoses and accelerating the hunt for a cure.

AskBio completes enrollment for a pivotal Phase 2 trial of a one-time gene therapy, potentially revolutionizing treatment for millions with heart failure.

The biopharma firm touts transformative drug data ahead, but with cash for only month-to-month operations, its future hangs by a precarious thread.

With FDA approval, soaring revenues, and game-changing clinical data, InspireMD prepares to spotlight its CGuard Prime stent for investors this April.

A new, imageable liver cancer therapy is one step closer to patients, thanks to a strategic partnership securing a vital US-based medical isotope supply.

A key U.S. patent extends protection for a promising CRPS-1 drug, paving the way for a potential first-in-class treatment for the debilitating condition.

Final trial data shows pralsetinib offers years of survival for RET+ lung cancer, but realizing its full potential hinges on overcoming diagnostic hurdles.

A new Phase 2 trial for an oral pill offers hope for patients with M. abscessus lung disease, a severe infection with no approved treatments.

Landmark study results show a new drug-coated balloon significantly improves outcomes for Peripheral Artery Disease, heralding a major shift in treatment.